Abstract
Purpose of review
This review focuses on the recent advances in cholestatic liver diseases. While there is an emphasis placed on translational and treatment-focused studies, basic science studies with the greatest impact on the field are also covered.Recent findings
Highlights include new discoveries for the role of the farsenoid X receptor and sodium-dependent taurocholate cotransporting polypeptide; new insights into the pathogenesis of progressive familial intrahepatic cholestasis type 1, biliary atresia, intrahepatic cholestasis of pregnancy, and primary biliary cirrhosis; new information for assessing prognosis in biliary atresia and primary biliary cirrhosis; and important clinical trials in intrahepatic cholestasis of pregnancy, primary biliary cirrhosis and primary sclerosing cholangitis.Summary
The studies of 2006 have furthered our understanding of cholestasis and cholestatic syndromes. While we continue to add to our knowledge of pathogenesis and treatment for many of these diseases, much work remains.References
Articles referenced by this article (28)
Benefit of farnesoid X receptor inhibition in obstructive cholestasis.
Proc Natl Acad Sci U S A, (30):11323-11328 2006
MED: 16844773
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
Gastroenterology, (6):1793-1806 2006
MED: 16697742
Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport.
Hepatology, (1):195-204 2006
MED: 16799980
Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation.
Hepatology, (5):1125-1134 2006
MED: 16628629
Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver.
Hepatology, (1):62-74 2006
MED: 16799996
Management of patients with biliary atresia in France: results of a decentralized policy 1986-2002.
Hepatology, (1):75-84 2006
MED: 16799986
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000.
J Pediatr, (4):467-474 2006
MED: 16647406
Expression of the interferon-induced Mx proteins in biliary atresia.
J Pediatr Surg, (6):1139-1143 2006
MED: 16769349
Increased CXCR3 expression associated with CD3-positive lymphocytes in the liver and biliary remnant in biliary atresia.
J Pediatr Surg, (5):950-954 2006
MED: 16677891
Show 10 more references (10 of 28)
Citations & impact
Impact metrics
Citations of article over time
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1097/mog.0b013e3280d942d8
Article citations
Liver fibrosis pathologies and potentials of RNA based therapeutics modalities.
Drug Deliv Transl Res, 14(10):2743-2770, 06 Mar 2024
Cited by: 0 articles | PMID: 38446352
Review
Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms.
Int J Mol Med, 38(6):1673-1682, 20 Oct 2016
Cited by: 9 articles | PMID: 27779646 | PMCID: PMC5117744
The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
Hepatology, 65(6):2005-2018, 28 Apr 2017
Cited by: 104 articles | PMID: 28120434 | PMCID: PMC5444993
Cholestasis induces reversible accumulation of periplakin in mouse liver.
BMC Gastroenterol, 13:116, 13 Jul 2013
Cited by: 2 articles | PMID: 23849208 | PMCID: PMC3716950
Use of hepatotoxic drugs in chronic liver disease.
J Patient Saf, 8(2):45-50, 01 Jun 2012
Cited by: 2 articles | PMID: 22525363
Review
Go to all (11) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Cholestasis and cholestatic syndromes.
Curr Opin Gastroenterol, 22(3):209-214, 01 May 2006
Cited by: 13 articles | PMID: 16550034
Review
Cholestasis and cholestatic syndromes.
Curr Opin Gastroenterol, 21(3):270-274, 01 May 2005
Cited by: 4 articles | PMID: 15818146
Review
The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Gastroenterologist, 2(1):74-79, 01 Mar 1994
Cited by: 12 articles | PMID: 8055235
Review
Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
J Hepatol, 23(3):283-289, 01 Sep 1995
Cited by: 38 articles | PMID: 8550992